A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy.
In a subset of patients with gastroesophageal reflux disease (GERD), symptoms persist in spite of proton pump inhibitor (PPI) therapy. Endoscopic gastroplication (EG) was reported to provide a novel therapeutic option in GERD. To evaluate symptomatic and objective outcome of EG in PPI refractory GERD, consecutive GERD patients with persisting reflux symptoms during at least 2 months double dose PPI were recruited for EG (Endocinch). Exclusion criteria were high-grade esophagitis, Barrett's esophagus, and hiatal hernia > 3 cm. Symptoms and PPI use were evaluated before and 1, 3, and 12 months after the EG; 24-hr pH monitoring off PPI was performed before and after 3 and 12 months. All data are given as mean +/- SD and were analyzed by Student's t test. Twenty patients (10 females; mean age, 45 +/- 11 years) were recruited. Under conscious sedation with midazolam (6 +/- 2 mg) and pethidine (53 +/- 5 mg), a mean of 2.0 +/- 0.2 sutures was applied during a procedure time of 33 +/- 6 min. Throat ache and mild epigastric pain for up to 3 days after the procedure were the only adverse events. At 3 and 12 months symptom score (11.6 +/- 6 vs. 6.4 +/- 3.7 [P < 0.01] and 7.1 +/- 4.5 [P < 0.05]) as well as pH monitoring (% time pH < 4: 17.0 +/- 11.1 vs. 8.1 +/- 5.7% [P < 0.01] and 9.8 +/- 4.1% [P < 0.01]) significantly improved. Ph monitoring was normalized (< 4% of time) in seven patients after 3 months. PPIs could be stopped in 13 patients, with 2 patients still using H2-blockers and 1 using cisapride after 3 months. After 12 months only six patients were free of PPI use and pH monitoring was normalized in six patients. We conclude that EG provides short- and medium-term symptomatic and objective relief to a subset of GERD patients refractory to high-dose PPI.
Arts
J
J
Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Lerut
T
T
Rutgeerts
P
P
Sifrim
D
D
Janssens
J
J
Tack
J
J
D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000601:surgery*; D015391:Gastroplasty / Q000379:methods*; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D013536:Suture Techniques
D054328:Proton Pump Inhibitors
J Gastrointest Surg. 1999 May-Jun;3(3):292-300
10481122
Gastrointest Endosc. 2001 Apr;53(4):416-22
11275879
Am J Gastroenterol. 1995 Jan;90(1):35-8
7801945
Gut. 2004 Aug;53(8):1207-14
15247192
Gut. 2003 Oct;52(10):1397-402
12970129
Gut. 2002 Oct;51(4):472-4
12235065
Am J Gastroenterol. 1996 Aug;91(8):1527-31
8759655
Gut. 2002 Oct;51(4):468-71
12235064
Surg Laparosc Endosc Percutan Tech. 2002 Aug;12(4):219-23
12193813
Scand J Gastroenterol Suppl. 1989;156:7-13
2662390
Gastrointest Endosc. 1994 Nov-Dec;40(6):722-9
7859971
Aliment Pharmacol Ther. 1995;9 Suppl 1:15-25
7495937
Gut. 2003 Jan;52(1):34-9
12477756
Surg Laparosc Endosc Percutan Tech. 2002 Oct;12(5):316-9
12409696
Gastrointest Endosc. 1996 Aug;44(2):133-43
8858318
J Laparoendosc Adv Surg Tech A. 2002 Oct;12(5):305-8
12470402
N Engl J Med. 1999 Mar 18;340(11):825-31
10080844
Dig Dis Sci. 2003 Jul;48(7):1213-20
12870775
JAMA. 2001 May 9;285(18):2331-8
11343480
Am J Dig Dis. 1976 Nov;21(11):953-6
984016
Am J Med. 2003 Jan;114(1):1-5
12543281
Gastrointest Endosc. 1986 Feb;32(1):36-8
3512359